<div class="article">
	<h3>Technology:
   Synergen Inc. Offering</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 12/24/90</li>
		</ul>
	</div>
	<p class="article-leader">BOULDER, Colo. -- Synergen Inc. said it expects to raise
$50 million in an offering of partnership units to finance
research and development of a potential treatment for
inflammatory diseases such as rheumatoid arthritis.
   The biotechnology concern said the partnership units will
own certain rights to the treatment, interleukin-1 receptor
antagonist, which is currently in human clinical trials.</p>
	<div class="article-body"><p>The company said it expects the partnership to be funded
in the first quarter of 1991.</p>
<p></p></div>
</div>
